From here to where?

When marketing new treatments to the wider world, APAC drug developers generally choose one of two regulatory paths: the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). 

Reading this whitepaper equips you to ask better questions and inform your decision-making when planning your pharmaceutical treatment’s route from APAC to the global market. Intended for drug developers in China, South Korea, Japan and the wider APAC region, this whitepaper explains the merits of FDA and EMA regulatory submissions and anticipates the challenges. 

Read it to learn:

• Why the EMA makes sense for some APAC sponsors
• Best practices for EMA submissions
• What the challenges and barriers are to EMA MAAs
• Why the FDA is more suitable for some APAC sponsors
• Recommendations for FDA submissions
• What the challenges and barriers are to FDA approval
• Tips for accessing the global market
• How APAC sponsors received FDA/EMA approvals, told through case studies